Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Immunome (IMNM) Accumulated Depreciation & Amortization (2019 - 2025)

Immunome filings provide 4 years of Accumulated Depreciation & Amortization readings, the most recent being $6.4 million for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 34.13% to $6.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.4 million, a 34.13% increase, with the full-year FY2025 number at $6.4 million, up 34.13% from a year prior.
  • Accumulated Depreciation & Amortization hit $6.4 million in Q4 2025 for Immunome, up from $4.7 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $6.4 million in Q4 2025 to a low of $3.5 million in Q4 2022.
  • Median Accumulated Depreciation & Amortization over the past 4 years was $4.3 million (2023), compared with a mean of $4.6 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: increased 13.24% in 2023 and later soared 34.13% in 2025.
  • Immunome's Accumulated Depreciation & Amortization stood at $3.5 million in 2022, then grew by 13.24% to $3.9 million in 2023, then increased by 21.52% to $4.7 million in 2024, then skyrocketed by 34.13% to $6.4 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $6.4 million (Q4 2025), $4.7 million (Q4 2024), and $3.9 million (Q4 2023) per Business Quant data.